©2017 by Dani Offen’s Laboratory for Translational Neuroscience. Proudly created with Wix.com

PUBLICATIONS

 

2017

 

Voluntary exercise improves cognitive deficits in female dominant-negative DISC1 transgenic mouse model of neuropsychiatric disorders.

Segal-Gavish H, Barzilay R, Rimoni O, Offen D.

World J Biol Psychiatry. 2017 Jun 8:1-10. doi: 10.1080/15622975.2017.1323118. 

Concise Review: Mesenchymal Stem Cells in Neurodegenerative Diseases.

Volkman R, Offen D.

Stem Cells. 2017 Jun 7. doi: 10.1002/stem.2651.Review.

A Multifunctional Biocompatible Drug Candidate is Highly Effective in Delaying Pathological Signs of Alzheimer's Disease in 5XFAD Mice.

Segal-Gavish H, Danino O, Barhum Y, Ben-Zur T, Shai E, Varon D, Offen D, Fischer B.

J Alzheimers Dis. 2017;58(2):389-400. doi: 10.3233/JAD-161236.

BDNF Overexpression Prevents Cognitive Deficit Elicited by Adolescent Cannabis Exposure and Host Susceptibility Interaction.

Segal-Gavish H, Gazit N, Barhum Y, Ben-Zur T, Taler M, Henry Hornfeld S, Gil-Ad I, Weizman A, Slutsky I, Niwa M, Kamiya A, Sawa A, Offen D, Barzilay R.

Hum Mol Genet. 2017 Apr 11. doi: 10.1093/hmg/ddx139. 

Long term beneficial effect of neurotrophic factors-secreting mesenchymal stem cells transplantation in the BTBR mouse model of autism.

Perets N, Segal-Gavish H, Gothelf Y, Barzilay R, Barhum Y, Abramov N, Hertz S, Morozov D, London M, Offen D.

Behav Brain Res. 2017 Jul 28;331:254-260. doi: 10.1016/j.bbr.2017.03.047.

 

Toll-like receptor 3 deficiency decreases epileptogenesis in a pilocarpine model of SE-induced epilepsy in mice.

Gross A, Benninger F, Madar R, Illouz T, Griffioen K, Steiner I, Offen D, Okun E.

Epilepsia. 2017 Apr;58(4):586-596. doi: 10.1111/epi.13688. 

2016

 

CD44 Deficiency Is Associated with Increased Susceptibility to Stress-Induced Anxiety-like Behavior in Mice.

Barzilay R, Ventorp F, Segal-Gavish H, Aharony I, Bieber A, Dar S, Vescan M, Globus R, Weizman A, Naor D, Lipton J, Janelidze S, Brundin L, Offen D.

J Mol Neurosci. 2016 Dec;60(4):548-558.

Reversal of ApoE4-Driven Brain Pathology by Vascular Endothelial Growth Factor Treatment.

Salomon-Zimri S, Glat MJ, Barhum Y, Luz I, Boehm-Cagan A, Liraz O, Ben-Zur T, Offen D, Michaelson DM.

J Alzheimers Dis. 2016 Jun 30;53(4):1443-58. doi: 10.3233/JAD-160182.

Neuroprotective Effect of a DJ-1 Based Peptide in a Toxin Induced Mouse Model of Multiple System Atrophy.

Glat MJ, Ben-Zur T, Barhum Y, Offen D.

PLoS One. 2016 Feb 22;11(2):e0148170. doi: 10.1371/journal.pone.0148170.

The CD44 ligand hyaluronic acid is elevated in the cerebrospinal fluid of suicide attempters and is associated with increased blood-brain barrier permeability.

Ventorp F, Barzilay R, Erhardt S, Samuelsson M, Träskman-Bendz L, Janelidze S, Weizman A, Offen D, Brundin L.

J Affect Disord. 2016 Mar 15;193:349-54. doi: 10.1016/j.jad.2015.12.069.

Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials.

Petrou P, Gothelf Y, Argov Z, Gotkine M, Levy YS, Kassis I, Vaknin-Dembinsky A, Ben-Hur T, Offen D, Abramsky O, Melamed E, Karussis D.

JAMA Neurol. 2016 Mar;73(3):337-44. doi: 10.1001/jamaneurol.2015.4321.

Multifactorial Gene Therapy Enhancing the Glutamate Uptake System and Reducing Oxidative Stress Delays Symptom Onset and Prolongs Survival in the SOD1-G93A ALS Mouse Model.

Benkler C, Barhum Y, Ben-Zur T, Offen D.

J Mol Neurosci. 2016 Jan;58(1):46-58. doi: 10.1007/s12031-015-0695-2. 

Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis.

Benninger F, Glat MJ, Offen D, Steiner I.

J Clin Neurosci. 2016 Apr;26:75-8. doi: 10.1016/j.jocn.2015.10.008.

Ectopic Muscle Expression of Neurotrophic Factors Improves Recovery After Nerve Injury.

Glat MJ, Benninger F, Barhum Y, Ben-Zur T, Kogan E, Steiner I, Yaffe D, Offen D.

J Mol Neurosci. 2016 Jan;58(1):39-45. doi: 10.1007/s12031-015-0648-9. 

Mesenchymal Stem Cell Transplantation Promotes Neurogenesis and Ameliorates Autism Related Behaviors in BTBR Mice.

Segal-Gavish H, Karvat G, Barak N, Barzilay R, Ganz J, Edry L, Aharony I, Offen D, Kimchi T.

Autism Res. 2016 Jan;9(1):17-32. doi: 10.1002/aur.1530. 

 

2015

A DJ-1 Based Peptide Attenuates Dopaminergic Degeneration in Mice Models of Parkinson's Disease via Enhancing Nrf2.

Lev N, Barhum Y, Ben-Zur T, Aharony I, Trifonov L, Regev N, Melamed E, Gruzman A, Offen D.

PLoS One. 2015 May 29;10(5):e0127549. doi: 10.1371/journal.pone.0127549. 

DJ-1 knockout augments disease severity and shortens survival in a mouse model of ALS.

Lev N, Barhum Y, Lotan I, Steiner I, Offen D.

PLoS One. 2015 Mar 30;10(3):e0117190. doi: 10.1371/journal.pone.0117190. 

A chemical chaperone-based drug candidate is effective in a mouse model of amyotrophic lateral sclerosis (ALS).

Getter T, Zaks I, Barhum Y, Ben-Zur T, Böselt S, Gregoire S, Viskind O, Shani T, Gottlieb H, Green O, Shubely M, Senderowitz H, Israelson A, Kwon I, Petri S, Offen D, Gruzman A.

ChemMedChem. 2015 May;10(5):850-61. doi: 10.1002/cmdc.201500045. 

A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits.

Aharony I, Ehrnhoefer DE, Shruster A, Qiu X, Franciosi S, Hayden MR, Offen D.

Hum Mol Genet. 2015 May 1;24(9):2604-14. doi: 10.1093/hmg/ddv023. 

Transplanted modified muscle progenitor cells expressing a mixture of neurotrophic factors delay disease onset and enhance survival in the SOD1 mouse model of ALS.

Dadon-Nachum M, Ben-Yaacov K, Ben-Zur T, Barhum Y, Yaffe D, Perlson E, Offen D.

J Mol Neurosci. 2015 Mar;55(3):788-97. doi: 10.1007/s12031-014-0426-0. 

PMID:

 

2014

Safety of repeated transplantations of neurotrophic factors-secreting human mesenchymal stromal stem cells.

Gothelf Y, Abramov N, Harel A, Offen D.

Clin Transl Med. 2014 Jul 10;3:21. doi: 10.1186/2001-1326-3-21.

Dopaminergic-like neurons derived from oral mucosa stem cells by developmental cues improve symptoms in the hemi-parkinsonian rat model.

Ganz J, Arie I, Buch S, Zur TB, Barhum Y, Pour S, Araidy S, Pitaru S, Offen D.

PLoS One. 2014 Jun 19;9(6):e100445. doi: 10.1371/journal.pone.0100445.

Alginate-coated magnetic nanoparticles for noninvasive MRI of extracellular calcium.

Bar-Shir A, Avram L, Yariv-Shoushan S, Anaby D, Cohen S, Segev-Amzaleg N, Frenkel D, Sadan O, Offen D, Cohen Y.

NMR Biomed. 2014 Jul;27(7):774-83. doi: 10.1002/nbm.3117.

Harnessing neurogenesis for the possible treatment of Parkinson's disease.

Lamm O, Ganz J, Melamed E, Offen D.

J Comp Neurol. 2014 Aug 15;522(12):2817-30. doi: 10.1002/cne.23607. Epub 2014 May 9. Review.

Astrocyte-like cells derived from human oral mucosa stem cells provide neuroprotection in vitro and in vivo.

Ganz J, Arie I, Ben-Zur T, Dadon-Nachum M, Pour S, Araidy S, Pitaru S, Offen D.

Stem Cells Transl Med. 2014 Mar;3(3):375-86. doi: 10.5966/sctm.2013-0074. 

Targeting neurogenesis ameliorates danger assessment in a mouse model of Alzheimer's disease.

Shruster A, Offen D.

Behav Brain Res. 2014 Mar 15;261:193-201. doi: 10.1016/j.bbr.2013.12.028. Epub 2013 Dec 31.

Rare combination of myasthenia and motor neuronopathy, responsive to Msc-Ntf stem cell therapy.

Petrou P, Argov A, Lennon VA, Gotkine M, Kassis I, Vaknin-Dembinsky A, Ben-Hur T, Offen D, Abramsky O, Melamed E, Karussis D.

Muscle Nerve. 2014 Mar;49(3):455-7. doi: 10.1002/mus.24143.

Dominant negative DISC1 mutant mice display specific social behaviour deficits and aberration in BDNF and cannabinoid receptor expression.

Kaminitz A, Barzilay R, Segal H, Taler M, Offen D, Gil-Ad I, Mechoulam R, Weizman A.

World J Biol Psychiatry. 2014 Jan;15(1):76-82. doi: 10.3109/15622975.2013.841993.

2013

Immunohistochemical analysis of sympathetic involvement in the SOD1-G93A transgenic mouse model of amyotrophic lateral sclerosis.

Kandinov B, Grigoriadis NC, Touloumi O, Drory VE, Offen D, Korczyn AD.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 Sep;14(5-6):424-33. doi: 10.3109/21678421.2013.780622.

Knocking out DJ-1 attenuates astrocytes neuroprotection against 6-hydroxydopamine toxicity.

Lev N, Barhum Y, Ben-Zur T, Melamed E, Steiner I, Offen D.

J Mol Neurosci. 2013 Jul;50(3):542-50. doi: 10.1007/s12031-013-9984-9. Epub 2013 Mar 28.

Cell and gene therapy in Alzheimer's disease.

Glat MJ, Offen D.

Stem Cells Dev. 2013 May 15;22(10):1490-6. doi: 10.1089/scd.2012.0633. Epub 2013 Mar 4. Review.

Altered astrocytic response to activation in SOD1(G93A) mice and its implications on amyotrophic lateral sclerosis pathogenesis.

Benkler C, Ben-Zur T, Barhum Y, Offen D.

Glia. 2013 Mar;61(3):312-26. doi: 10.1002/glia.22428.

Mesenchymal stem cells protect from sub-chronic phencyclidine insult in vivo and counteract changes in astrocyte gene expression in vitro.

Barzilay R, Ganz J, Sadan O, Ben-Zur T, Bren Z, Hinden N, Taler M, Lev N, Gil-Ad I, Weizman A, Offen D.

Eur Neuropsychopharmacol. 2013 Sep;23(9):1115-23. doi: 10.1016/j.euroneuro.2012.10.002. 

2012

Intrastriatal transplantation of neurotrophic factor-secreting human mesenchymal stem cells improves motor function and extends survival in R6/2 transgenic mouse model for Huntington's disease.

Sadan O, Melamed E, Offen D.

PLoS Curr. 2012 Jul 10;4:e4f7f6dc013d4e. doi: 10.1371/4f7f6dc013d4e.

DJ-1 protects against dopamine toxicity: implications for Parkinson's disease and aging.

Lev N, Barhum Y, Pilosof NS, Ickowicz D, Cohen HY, Melamed E, Offen D.

J Gerontol A Biol Sci Med Sci. 2013 Mar;68(3):215-25. doi: 10.1093/gerona/gls147.

Wnt signaling enhances neurogenesis and improves neurological function after focal ischemic injury.

Shruster A, Ben-Zur T, Melamed E, Offen D.

PLoS One. 2012;7(7):e40843. doi: 10.1371/journal.pone.0040843. 

Transplantation of placenta-derived mesenchymal stem cells in the EAE mouse model of MS.

Fisher-Shoval Y, Barhum Y, Sadan O, Yust-Katz S, Ben-Zur T, Lev N, Benkler C, Hod M, Melamed E, Offen D.

J Mol Neurosci. 2012 Sep;48(1):176-84. doi: 10.1007/s12031-012-9805-6.

Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington's disease.

Sadan O, Shemesh N, Barzilay R, Dadon-Nahum M, Blumenfeld-Katzir T, Assaf Y, Yeshurun M, Djaldetti R, Cohen Y, Melamed E, Offen D.

Exp Neurol. 2012 Apr;234(2):417-27. doi: 10.1016/j.expneurol.2011.12.045.

Therapeutic effect of myogenic cells modified to express neurotrophic factors in a rat model of sciatic nerve injury.

Dadon-Nachum M, Ben-Zur T, Srugo I, Shamir HM, Melamed E, Yaffe D, Offen D.

J Stem Cells Regen Med. 2012 Apr 14;8(1):21-7. 

Mapping apparent eccentricity and residual ensemble anisotropy in the gray matter using angular double-pulsed-field-gradient MRI.

Shemesh N, Barazany D, Sadan O, Bar L, Zur Y, Barhum Y, Sochen N, Offen D, Assaf Y, Cohen Y.

Magn Reson Med. 2012 Sep;68(3):794-806. doi: 10.1002/mrm.23300. 

Placental mesenchymal stromal cells induced into neurotrophic factor-producing cells protect neuronal cells from hypoxia and oxidative stress.

Yust-Katz S, Fisher-Shoval Y, Barhum Y, Ben-Zur T, Barzilay R, Lev N, Hod M, Melamed E, Offen D.

Cytotherapy. 2012 Jan;14(1):45-55. doi: 10.3109/14653249.2011.613928. 

 

 

2011

Stem cells treatment for sciatic nerve injury.

Dadon-Nachum M, Melamed E, Offen D.

Expert Opin Biol Ther. 2011 Dec;11(12):1591-7. doi: 10.1517/14712598.2011.628933. Review.

 

Cell replacement therapy for Parkinson's disease: how close are we to the clinic?

Ganz J, Lev N, Melamed E, Offen D.

Expert Rev Neurother. 2011 Sep;11(9):1325-39. doi: 10.1586/ern.11.74. Review.

PMID:

 

Striatal microinjection of Sydenham chorea antibodies: using a rat model to examine the dopamine hypothesis.

Ben-Pazi H, Sadan O, Offen D.

J Mol Neurosci. 2012 Jan;46(1):162-6. doi: 10.1007/s12031-011-9559-6.

Differentiated mesenchymal stem cells for sciatic nerve injury.

Dadon-Nachum M, Sadan O, Srugo I, Melamed E, Offen D.

Stem Cell Rev. 2011 Sep;7(3):664-71. doi: 10.1007/s12015-010-9227-1.

Intracerebral adult stem cells transplantation increases brain-derived neurotrophic factor levels and protects against phencyclidine-induced social deficit in mice.

Barzilay R, Ben-Zur T, Sadan O, Bren Z, Taler M, Lev N, Tarasenko I, Uzan R, Gil-Ad I, Melamed E, Weizman A, Offen D.

Transl Psychiatry. 2011 Dec 13;1:e61. doi: 10.1038/tp.2011.64.

Wnt signaling pathway overcomes the disruption of neuronal differentiation of neural progenitor cells induced by oligomeric amyloid β-peptide.

Shruster A, Eldar-Finkelman H, Melamed E, Offen D.

J Neurochem. 2011 Feb;116(4):522-9. doi: 10.1111/j.1471-4159.2010.07131.

 

The "dying-back" phenomenon of motor neurons in ALS.

Dadon-Nachum M, Melamed E, Offen D.

J Mol Neurosci. 2011 Mar;43(3):470-7. doi: 10.1007/s12031-010-9467-1. Review.

Intravitreal injections of neurotrophic factors secreting mesenchymal stem cells are neuroprotective in rat eyes following optic nerve transection.

Levkovitch-Verbin H, Sadan O, Vander S, Rosner M, Barhum Y, Melamed E, Offen D, Melamed S.

Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6394-400. doi: 10.1167/iovs.09-4310.

Mesenchymal stem cells stimulate endogenous neurogenesis in the subventricular zone of adult mice.

Kan I, Barhum Y, Melamed E, Offen D.

Stem Cell Rev. 2011 Jun;7(2):404-12. doi: 10.1007/s12015-010-9190-x.

2010

Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application.

Benkler C, Offen D, Melamed E, Kupershmidt L, Amit T, Mandel S, Youdim MB, Weinreb O.

EPMA J. 2010 Jun;1(2):343-61. doi: 10.1007/s13167-010-0026-1.

 

Neurogenesis in the aged and neurodegenerative brain.

Shruster A, Melamed E, Offen D.

Apoptosis. 2010 Nov;15(11):1415-21. doi: 10.1007/s10495-010-0491-y. Review.

 

Longitudinal MRI and MRSI characterization of the quinolinic acid rat model for excitotoxicity: peculiar apparent diffusion coefficients and recovery of N-acetyl aspartate levels.

Shemesh N, Sadan O, Melamed E, Offen D, Cohen Y.

NMR Biomed. 2010 Feb;23(2):196-206. doi: 10.1002/nbm.1443.

 

Intracerebroventricular transplantation of human mesenchymal stem cells induced to secrete neurotrophic factors attenuates clinical symptoms in a mouse model of multiple sclerosis.

Barhum Y, Gai-Castro S, Bahat-Stromza M, Barzilay R, Melamed E, Offen D.

J Mol Neurosci. 2010 May;41(1):129-37. doi: 10.1007/s12031-009-9302-8. 

2009

 

Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases.

Sadan O, Melamed E, Offen D.

Expert Opin Biol Ther. 2009 Dec;9(12):1487-97. doi: 10.1517/14712590903321439. Review.

 

Adult neurotrophic factor-secreting stem cells: a potential novel therapy for neurodegenerative diseases.

Sadan O, Shemesh N, Cohen Y, Melamed E, Offen D.

Isr Med Assoc J. 2009 Apr;11(4):201-4.

Introducing transcription factors to multipotent mesenchymal stem cells: making transdifferentiation possible.

Barzilay R, Melamed E, Offen D.

Stem Cells. 2009 Oct;27(10):2509-15. doi: 10.1002/stem.172. Review.

 

Comparative characterization of bone marrow-derived mesenchymal stromal cells from four different rat strains.

Barzilay R, Sadan O, Melamed E, Offen D.

Cytotherapy. 2009;11(4):435-42. doi: 10.1080/14653240902849796.

 

Accelerated proteasomal activity induced by Pb2+, Ga3+, or Cu2+ exposure does not induce degradation of alpha-synuclein.

Grunberg-Etkovitz N, Lev N, Ickowicz D, Avital A, Offen D, Malik Z.

J Environ Pathol Toxicol Oncol. 2009;28(1):5-24.

 

Lentiviral delivery of LMX1a enhances dopaminergic phenotype in differentiated human bone marrow mesenchymal stem cells.

Barzilay R, Ben-Zur T, Bulvik S, Melamed E, Offen D.

Stem Cells Dev. 2009 May;18(4):591-601. doi: 10.1089/scd.2008.0138.

Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease.

Sadan O, Bahat-Stromza M, Barhum Y, Levy YS, Pisnevsky A, Peretz H, Ilan AB, Bulvik S, Shemesh N, Krepel D, Cohen Y, Melamed E, Offen D.

Stem Cells Dev. 2009 Oct;18(8):1179-90. doi: 10.1089/scd.2008.0411.

Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson's disease.

Bahat-Stroomza M, Barhum Y, Levy YS, Karpov O, Bulvik S, Melamed E, Offen D.

J Mol Neurosci. 2009 Sep;39(1-2):199-210. doi: 10.1007/s12031-008-9166-3.

DJ-1 protects against dopamine toxicity.

Lev N, Ickowicz D, Barhum Y, Lev S, Melamed E, Offen D.

J Neural Transm (Vienna). 2009 Feb;116(2):151-60. doi: 10.1007/s00702-008-0134-4.

 

DJ-1 changes in G93A-SOD1 transgenic mice: implications for oxidative stress in ALS.

Lev N, Ickowicz D, Barhum Y, Melamed E, Offen D.

J Mol Neurosci. 2009 Jun;38(2):94-102. doi: 10.1007/s12031-008-9138-7.

Spinal cord mRNA profile in patients with ALS: comparison with transgenic mice expressing the human SOD-1 mutant.

Offen D, Barhum Y, Melamed E, Embacher N, Schindler C, Ransmayr G.

J Mol Neurosci. 2009 Jun;38(2):85-93. doi: 10.1007/s12031-007-9004-z.

 

2008

Progressive damage along the optic nerve following induction of crush injury or rodent anterior ischemic optic neuropathy in transgenic mice.

Dratviman-Storobinsky O, Hasanreisoglu M, Offen D, Barhum Y, Weinberger D, Goldenberg-Cohen N.

Mol Vis. 2008;14:2171-9. 

Migration of neurotrophic factors-secreting mesenchymal stem cells toward a quinolinic acid lesion as viewed by magnetic resonance imaging.

Sadan O, Shemesh N, Barzilay R, Bahat-Stromza M, Melamed E, Cohen Y, Offen D.

Stem Cells. 2008 Oct;26(10):2542-51. doi: 10.1634/stemcells.2008-0240. 

Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease.

Levy YS, Bahat-Stroomza M, Barzilay R, Burshtein A, Bulvik S, Barhum Y, Panet H, Melamed E, Offen D.

Cytotherapy. 2008;10(4):340-52. doi: 10.1080/14653240802021330.

Induction of human mesenchymal stem cells into dopamine-producing cells with different differentiation protocols.

Barzilay R, Kan I, Ben-Zur T, Bulvik S, Melamed E, Offen D.

Stem Cells Dev. 2008 Jun;17(3):547-54. doi: 10.1089/scd.2007.0172.

Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection.

Lev N, Ickowicz D, Melamed E, Offen D.

Neurotoxicology. 2008 May;29(3):397-405. doi: 10.1016/j.neuro.2008.01.007.

2007

Toxic causes of parkinsonism.

Lev N, Melamed E, Offen D.

Handb Clin Neurol. 2007;84:385-98. doi: 10.1016/S0072-9752(07)84050-4.

 

 

Intrastriatal transplantation of mouse bone marrow-derived stem cells improves motor behavior in a mouse model of Parkinson's disease.

Offen D, Barhum Y, Levy YS, Burshtein A, Panet H, Cherlow T, Melamed E.

J Neural Transm Suppl. 2007;(72):133-43.

Role of DJ-1 in parkinson's disease.

Lev N, Roncevich D, Ickowicz D, Melamed E, Offen D.

J Mol Neurosci. 2007 Mar;31(3):307. 

 

Bax ablation protects against hepatic ischemia/reperfusion injury in transgenic mice.

Ben-Ari Z, Pappo O, Cheporko Y, Yasovich N, Offen D, Shainberg A, Leshem D, Sulkes J, Vidne BA, Hochhauser E.

Liver Transpl. 2007 Aug;13(8):1181-8.

 

Autotransplantation of bone marrow-derived stem cells as a therapy for neurodegenerative diseases.

Kan I, Melamed E, Offen D.

Handb Exp Pharmacol. 2007;(180):219-42. Review.

 

Dopaminergic differentiation of human mesenchymal stem cells--utilization of bioassay for tyrosine hydroxylase expression.

Kan I, Ben-Zur T, Barhum Y, Levy YS, Burstein A, Charlow T, Bulvik S, Melamed E, Offen D.

Neurosci Lett. 2007 May 23;419(1):28-33. Epub 2007 Apr 13.

 

Bax deficiency reduces infarct size and improves long-term function after myocardial infarction.

Hochhauser E, Cheporko Y, Yasovich N, Pinchas L, Offen D, Barhum Y, Pannet H, Tobar A, Vidne BA, Birk E.

Cell Biochem Biophys. 2007;47(1):11-20.

 

Docosahexaenoic acid and arachidonic acid are fundamental supplements for the induction of neuronal differentiation.

Kan I, Melamed E, Offen D, Green P.

J Lipid Res. 2007 Mar;48(3):513-7.

 

Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model.

Grunfeld JF, Barhum Y, Blondheim N, Rabey JM, Melamed E, Offen D.

Exp Neurol. 2007 Mar;204(1):260-3.

2006

 

Experimental encephalomyelitis induces changes in DJ-1: implications for oxidative stress in multiple sclerosis.

Lev N, Ickowicz D, Barhum Y, Blondheim N, Melamed E, Offen D.

Antioxid Redox Signal. 2006 Nov-Dec;8(11-12):1987-95.

 

Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current state.

Gilgun-Sherki Y, Melamed E, Offen D.

Curr Pharm Des. 2006;12(27):3509-19. Review.

 

Human mesenchymal stem cells express neural genes, suggesting a neural predisposition.

Blondheim NR, Levy YS, Ben-Zur T, Burshtein A, Cherlow T, Kan I, Barzilai R, Bahat-Stromza M, Barhum Y, Bulvik S, Melamed E, Offen D.

Stem Cells Dev. 2006 Apr;15(2):141-64.

 

Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage.

Lev N, Melamed E, Offen D.

Neurosci Lett. 2006 May 15;399(1-2):27-32. Epub 2006 Apr 11.

 

Adult stem cells for neuronal repair.

Barzilay R, Levy YS, Melamed E, Offen D.

Isr Med Assoc J. 2006 Jan;8(1):61-6. Review.

Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents.

Hellmann MA, Panet H, Barhum Y, Melamed E, Offen D.

Neurosci Lett. 2006 Mar 6;395(2):124-8. Epub 2005 Dec 15.

2005

 

A novel brain-targeted antioxidant (AD4) attenuates haloperidol-induced abnormal movement in rats: implications for tardive dyskinesia.

Sadan O, Bahat-Stromza M, Gilgun-Sherki Y, Atlas D, Melamed E, Offen D.

Clin Neuropharmacol. 2005 Nov-Dec;28(6):285-8.

 

Analysis of gene expression in MOG-induced experimental autoimmune encephalomyelitis after treatment with a novel brain-penetrating antioxidant.

Gilgun-Sherki Y, Barhum Y, Atlas D, Melamed E, Offen D.

J Mol Neurosci. 2005;27(1):125-35.

Therapeutic potential of neurotrophic factors in neurodegenerative diseases.

Levy YS, Gilgun-Sherki Y, Melamed E, Offen D.

BioDrugs. 2005;19(2):97-127. Review.

A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease.

Bahat-Stroomza M, Gilgun-Sherki Y, Offen D, Panet H, Saada A, Krool-Galron N, Barzilai A, Atlas D, Melamed E.

Eur J Neurosci. 2005 Feb;21(3):637-46.

Integral therapeutic potential of bone marrow mesenchymal stem cells.

Kan I, Melamed E, Offen D.

Curr Drug Targets. 2005 Feb;6(1):31-41. Review.

2004

Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease.

Elkon H, Melamed E, Offen D.

J Mol Neurosci. 2004;24(3):387-400.

Embryonic and adult stem cells as a source for cell therapy in Parkinson's disease.

Levy YS, Stroomza M, Melamed E, Offen D.

J Mol Neurosci. 2004;24(3):353-86. Review.

Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease.

Gilgun-Sherki Y, Djaldetti R, Melamed E, Offen D.

Pharmacogenomics J. 2004;4(5):291-306. Review.

 

A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis.

Offen D, Gilgun-Sherki Y, Barhum Y, Benhar M, Grinberg L, Reich R, Melamed E, Atlas D.

J Neurochem. 2004 Jun;89(5):1241-51.

Bax-ablation attenuates experimental autoimmune encephalomyelitis in mice.

Lev N, Barhum Y, Melamed E, Offen D.

Neurosci Lett. 2004 Apr 15;359(3):139-42.

 

The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy.

Gilgun-Sherki Y, Melamed E, Offen D.

J Neurol. 2004 Mar;251(3):261-8. Review.

2003

 

Induction of neuron-specific enolase promoter and neuronal markers in differentiated mouse bone marrow stromal cells.

Levy YS, Merims D, Panet H, Barhum Y, Melamed E, Offen D.

J Mol Neurosci. 2003;21(2):121-32.

Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis.

Gilgun-Sherki Y, Panet H, Melamed E, Offen D.

Brain Res. 2003 Nov 7;989(2):196-204.

 

Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis.

Gilgun-Sherki Y, Panet H, Holdengreber V, Mosberg-Galili R, Offen D.

Neurosci Res. 2003 Oct;47(2):201-7.

 

Antioxidant treatment in Alzheimer's disease: current state.

Gilgun-Sherki Y, Melamed E, Offen D.

J Mol Neurosci. 2003;21(1):1-11. Review.

 

The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.

Gilgun-Sherki Y, Melamed E, Mechoulam R, Offen D.

Pharmacol Toxicol. 2003 Aug;93(2):66-70.

 

Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.

Gilgun-Sherki Y, Melamed E, Ziv I, Offen D.

Pharmacol Toxicol. 2003 Jul;93(1):54-6. 

 

Bax ablation protects against myocardial ischemia-reperfusion injury in transgenic mice.

Hochhauser E, Kivity S, Offen D, Maulik N, Otani H, Barhum Y, Pannet H, Shneyvays V, Shainberg A, Goldshtaub V, Tobar A, Vidne BA.

Am J Physiol Heart Circ Physiol. 2003 Jun;284(6):H2351-9.

Apoptosis and Parkinson's disease.

Lev N, Melamed E, Offen D.

Prog Neuropsychopharmacol Biol Psychiatry. 2003 Apr;27(2):245-50. Review.

The molecular mechanisms of dopamine toxicity.

Barzilai A, Daily D, Zilkha-Falb R, Ziv I, Offen D, Melamed E, Shirvan A.

Adv Neurol. 2003;91:73-82. Review.

2002

Hemin-induced apoptosis in PC12 and neuroblastoma cells: implications for local neuronal death associated with intracerebral hemorrhage.

Levy YS, Streifler JY, Panet H, Melamed E, Offen D.

Neurotox Res. 2002 Nov-Dec;4(7-8):609-616.

 

Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase.

Elkon H, Don J, Melamed E, Ziv I, Shirvan A, Offen D.

J Mol Neurosci. 2002 Jun;18(3):229-38.

Antioxidant therapy in acute central nervous system injury: current state.

Gilgun-Sherki Y, Rosenbaum Z, Melamed E, Offen D.

Pharmacol Rev. 2002 Jun;54(2):271-84. Review.

2001

6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease.

Elkon H, Melamed E, Offen D.

Cell Mol Neurobiol. 2001 Dec;21(6):771-81.

Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease.

Offen D, Shtaif B, Hadad D, Weizman A, Melamed E, Gil-Ad I.

Neurosci Lett. 2001 Dec 28;316(3):129-32.

Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier.

Gilgun-Sherki Y, Melamed E, Offen D.

Neuropharmacology. 2001 Jun;40(8):959-75. Review.

Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells.

Panet H, Barzilai A, Daily D, Melamed E, Offen D.

J Neurochem. 2001 Apr;77(2):391-8.

Catechol-O-methyltransferase decreases levodopa toxicity in vitro.

Offen D, Panet H, Galili-Mosberg R, Melamed E.

Clin Neuropharmacol. 2001 Jan-Feb;24(1):27-30.

Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by dual activation of the ras-phosphoinositide 3-kinase and jun n-terminal kinase pathways.

Daily D, Vlamis-Gardikas A, Offen D, Mittelman L, Melamed E, Holmgren A, Barzilai A.

J Biol Chem. 2001 Jun 15;276(24):21618-26.

Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Vila M, Jackson-Lewis V, Vukosavic S, Djaldetti R, Liberatore G, Offen D, Korsmeyer SJ, Przedborski S.

Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2837-42.

Molecular biology of dopamine-induced apoptosis : possible implications for Parkinson's disease.

Ziv I, Shirvan A, Offen D, Barzilai A, Melamed E.

Methods Mol Med. 2001;62:73-87. doi: 10.1385/1-59259-142-6:73.

2000

Mice overexpressing Bcl-2 in their neurons are resistant to myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE).

Offen D, Kaye JF, Bernard O, Merims D, Coire CI, Panet H, Melamed E, Ben-Nun A.

J Mol Neurosci. 2000 Dec;15(3):167-76.

Haloperidol-induced neurotoxicity--possible implications for tardive dyskinesia.

Galili R, Mosberg, Gil-Ad I, Weizman A, Melamed E, Offen D.

J Neural Transm (Vienna). 2000;107(4):479-90.

The molecular mechanism of dopamine-induced apoptosis: identification and characterization of genes that mediate dopamine toxicity.

Barzilai A, Zilkha-Falb R, Daily D, Stern N, Offen D, Ziv I, Melamed E, Shirvan A.

J Neural Transm Suppl. 2000;(60):59-76.

Apoptosis as a general cell death pathway in neurodegenerative diseases.

Offen D, Elkon H, Melamed E.

J Neural Transm Suppl. 2000;(58):153-66. Review.

Levodopa--an exotoxin or a therapeutic drug?

Melamed E, Offen D, Shirvan A, Ziv I.

J Neurol. 2000 Apr;247 Suppl 2:II135-9. Review.

 

Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease.

Offen D, Sherki Y, Melamed E, Fridkin M, Brenneman DE, Gozes I.

Brain Res. 2000 Jan 31;854(1-2):257-62.

Developmental changes in antioxidant enzymes and oxidative damage in kidneys, liver and brain of bcl-2 knockout mice.

Hochman A, Liang H, Offen D, Melamed E, Sternin H.

Cell Mol Biol (Noisy-le-grand). 2000 Feb;46(1):41-52.

1999

Oxidative stress and neuroprotection in Parkinson's disease: implications from studies on dopamine-induced apoptosis.

Offen D, Hochman A, Gorodin S, Ziv I, Shirvan A, Barzilai A, Melamed E.

Adv Neurol. 1999;80:265-9. Review.

The involvement of p53 in dopamine-induced apoptosis of cerebellar granule neurons and leukemic cells overexpressing p53.

Daily D, Barzilai A, Offen D, Kamsler A, Melamed E, Ziv I.

Cell Mol Neurobiol. 1999 Apr;19(2):261-76.

 

Dopamine-melanin is actively phagocytized by PC12 cells and cerebellar granular cells: possible implications for the etiology of Parkinson's disease.

Offen D, Gorodin S, Melamed E, Hanania J, Malik Z.

Neurosci Lett. 1999 Jan 29;260(2):101-4.

1998

 

Antibodies from ALS patients inhibit dopamine release mediated by L-type calcium channels.

Offen D, Halevi S, Orion D, Mosberg R, Stern-Goldberg H, Melamed E, Atlas D.

Neurology. 1998 Oct;51(4):1100-3.

 

Levodopa toxicity and apoptosis.

Melamed E, Offen D, Shirvan A, Djaldetti R, Barzilai A, Ziv I.

Ann Neurol. 1998 Sep;44(3 Suppl 1):S149-54. Review.

 

Enhanced oxidative stress and altered antioxidants in brains of Bcl-2-deficient mice.

Hochman A, Sternin H, Gorodin S, Korsmeyer S, Ziv I, Melamed E, Offen D.

J Neurochem. 1998 Aug;71(2):741-8.

HTLV-1 in mouthwash cells from a TSP/HAM patient and asymptomatic carriers.

Offen D, Achiron A, Wasserman L, Miller M, Shaklai M, Dabby R, Gorodin S, Shohat B.

Arch Virol. 1998;143(5):1029-34.

 

Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity.

Offen D, Beart PM, Cheung NS, Pascoe CJ, Hochman A, Gorodin S, Melamed E, Bernard R, Bernard O.

Proc Natl Acad Sci U S A. 1998 May 12;95(10):5789-94.

1997

 

Dopamine-melanin induces apoptosis in PC12 cells; possible implications for the etiology of Parkinson's disease.

Offen D, Ziv I, Barzilai A, Gorodin S, Glater E, Hochman A, Melamed E.

Neurochem Int. 1997 Aug;31(2):207-16.

Dopamine-induced apoptosis is inhibited in PC12 cells expressing Bcl-2.

Offen D, Ziv I, Panet H, Wasserman L, Stein R, Melamed E, Barzilai A.

Cell Mol Neurobiol. 1997 Jun;17(3):289-304.

 

Monoamine-induced apoptotic neuronal cell death.

Zilkha-Falb R, Ziv I, Nardi N, Offen D, Melamed E, Barzilai A.

Cell Mol Neurobiol. 1997 Feb;17(1):101-18.

 

The proto-oncogene Bcl-2 inhibits cellular toxicity of dopamine: possible implications for Parkinson's disease.

Ziv I, Offen D, Haviv R, Stein R, Panet H, Zilkha-Falb R, Shirvan A, Barzilai A, Melamed E.

Apoptosis. 1997;2(2):149-55.

 

Modulation of control mechanisms of dopamine-induced apoptosis--a future approach to the treatment of Parkinson's disease?

Ziv I, Offen D, Barzilai A, Haviv R, Stein R, Zilkha-Falb R, Shirvan A, Melamed E.

J Neural Transm Suppl. 1997;49:195-202. Review.

 

Nigrostriatal neuronal death in Parkinson's disease--a passive or an active genetically-controlled process?

Ziv I, Barzilai A, Offen D, Nardi N, Melamed E.

J Neural Transm Suppl. 1997;49:69-76. Review.

 

Levodopa induces apoptosis in cultured neuronal cells--a possible accelerator of nigrostriatal degeneration in Parkinson's disease?

Ziv I, Zilkha-Falb R, Offen D, Shirvan A, Barzilai A, Melamed E.

Mov Disord. 1997 Jan;12(1):17-23.

1996

 

Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease.

Offen D, Ziv I, Sternin H, Melamed E, Hochman A.

Exp Neurol. 1996 Sep;141(1):32-9.

 

Detection of proviral human T-cell lymphotrophic virus type I DNA in mouthwash samples of HAM/TSP patients and HTLV-I carriers.

Achiron A, Pinhas-Hamiel O, Barak Y, Doll L, Offen D, Djaldetti R, Frankel G, Shohat B.

Arch Virol. 1996;141(1):147-53.

 

Dopamine-induced, genotoxic activation of programmed cell death. A role in nigrostriatal neuronal degeneration in Parkinson's disease?

Ziv I, Barzilai A, Offen D, Stein R, Achiron A, Melamed E.

Adv Neurol. 1996;69:229-33. Review.

1995

 

Dopamine-induced programmed cell death in mouse thymocytes.

Offen D, Ziv I, Gorodin S, Barzilai A, Malik Z, Melamed E.

Biochim Biophys Acta. 1995 Aug 31;1268(2):171-7.

1994

Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons--a possible novel pathogenetic mechanism in Parkinson's disease.

Ziv I, Melamed E, Nardi N, Luria D, Achiron A, Offen D, Barzilai A.

Neurosci Lett. 1994 Mar 28;170(1):136-40.

1992

 

Induction of tolerance to an IgG autoantibody.

Offen D, Spatz L, Escowitz H, Factor S, Diamond B.

Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8332-6.

1991

Possible involvement of (2'5')oligoadenylate synthetase activity in pre-mRNA splicing.

Sperling J, Chebath J, Arad-Dann H, Offen D, Spann P, Lehrer R, Goldblatt D, Jolles B, Sperling R.

Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10377-81.

A novel splicing factor is an integral component of 200S large nuclear ribonucleoprotein (InRNP) particles.

Ast G, Goldblatt D, Offen D, Sperling J, Sperling R.

EMBO J. 1991 Feb;10(2):425-32.

1990

Monoclonal anti-La antibody derived from a mouse with experimental SLE is similar to human anti-La antibodies.

Offen D, Mendlovic S, Fricke H, Sperling R, Sperling J, Mozes E.

J Autoimmun. 1990 Dec;3(6):701-13.

Pathogenic anti-DNA antibodies in SLE: idiotypic families and genetic origins.

Paul E, Manheimer-Lory A, Livneh A, Solomon A, Aranow C, Ghossein C, Shefner R, Offen D, Pillinger M, Diamond B.

Int Rev Immunol. 1990;5(3-4):295-313. Review.

Identification of nuclear RNP proteins as pre-mRNA splicing factors.

Ast G, Offen D, Goldblatt D, Sperling R, Sperling J.

Mol Biol Rep. 1990;14(2-3):193. 

Induction of experimental systemic lupus erythematosus in mice by immunization with a monoclonal anti-La autoantibody.

Fricke H, Offen D, Mendlovic S, Shoenfeld Y, Bakimer R, Sperling J, Mozes E.

Int Immunol. 1990;2(3):225-30.

1987

Autoantibodies against a specific nuclear RNP protein in sera of patients with autoimmune rheumatic diseases associated with myositis.

Arad-Dann H, Isenberg DA, Shoenfeld Y, Offen D, Sperling J, Sperling R.

J Immunol. 1987 Apr 15;138(8):2463-8.

1986

U1, U2, and U6 small nuclear ribonucleoproteins (snRNPs) are associated with large nuclear RNP particles containing transcripts of an amplified gene in vivo.

Sperling R, Spann P, Offen D, Sperling J.

Proc Natl Acad Sci U S A. 1986 Sep;83(18):6721-5.